Sign In
27 Jul 2020 09:00
Horizon Discovery Group plc
27 July 2020
Horizon Discovery Group plc
Block Listing Six Monthly Return
27 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon") provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:
Name of applicant: | Horizon Discovery Group plc
|
Name of scheme(s): | a) Horizon Discovery Limited Enterprise Management Incentive Share Option Scheme b) Horizon Discovery Group plc Long Term Incentive Plan c) Horizon Discovery 2014 Sharesave Scheme d) Horizon Discovery Group plc US Employee Stock Purchase Plan
|
Period of return (from / to): | From 26 January 2020 to 25 July 2020 |
Number of securities admitted and date of admission | Total of 3,000,000 ordinary shares of 1p each, admission date 26 July 2017, split: a) 1,398,000 b) 1,392,000 c) 110,000 d) 100,000 Further 500,000 ordinary shares of 1p each, admission date 27 July 2018, split: a) 0 b) 150,000 c) 150,000 d) 200,000 Further 1,500,000 ordinary shares of 1p each, admission date 28 October 2019, split: a) 0 b) 500,000 c) 500,000 d) 500,000
|
Balance of unallotted securities under schemes from previous return: | Total of 2,983,644 ordinary shares of 1p each, split: a) 602,425 b) 1,352,676 c) 567,971 d) 460,572
|
Less: Number of securities issued/allotted under scheme(s) during period: | Total of 534,264 ordinary shares of 1p each, split: a) 478,340 b) 52,760 c) 3,164 d) 0
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | Total of 2,449,380 ordinary shares of 1p each, split: a) 124,085 b) 1,299,916 c) 564,807 d) 460,572 |
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
Jon Davies, Head of Investor Relations
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Freddie Barnfield/Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (UK Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
Westwicke, an ICR Company (US Investor Relations)
Stephanie Carrington
Tel. +1 646-277-1282
Email: horizondisovery@icrinc.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development. Horizon's portfolio of tools and services is built on decades of experience in altering the expression of genes across mammalian and human cell types to provide cell engineering tools and services to customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications. Horizon's offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine. Horizon's customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organisations and academic researchers across the globe.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.
Follow the stocks
